Nurix Financial Statements From 2010 to 2025

NRIX Stock  USD 11.27  0.11  0.99%   
Nurix Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nurix Therapeutics' valuation are provided below:
Nurix Therapeutics does not presently have any fundamental ratios for analysis.
Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Nurix Therapeutics Company Return On Equity Analysis

Nurix Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Nurix Therapeutics Return On Equity

    
  -0.64  
Most of Nurix Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nurix Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Nurix Therapeutics has a Return On Equity of -0.6416. This is 97.32% lower than that of the Biotechnology sector and 98.24% lower than that of the Health Care industry. The return on equity for all United States stocks is 106.97% higher than that of the company.

Nurix Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Nurix Therapeutics's current stock value. Our valuation model uses many indicators to compare Nurix Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nurix Therapeutics competition to find correlations between indicators driving Nurix Therapeutics's intrinsic value. More Info.
Nurix Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nurix Therapeutics' earnings, one of the primary drivers of an investment's value.

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.